160 related articles for article (PubMed ID: 24070006)
21. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
22. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
23. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
25. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):449-56. PubMed ID: 24529941
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activity of ceftaroline and comparator agents against nosocomial Gram-negative and Gram-positive clinically significant bacterial isolates from patients in a teaching hospital in Kuwait.
Jamal W; Abdulkareem H; Rotimi VO
J Chemother; 2018 Jul; 30(4):213-223. PubMed ID: 29466931
[TBL] [Abstract][Full Text] [Related]
28. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
Jones RN; Farrell DJ; Mendes RE; Sader HS
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii69-80. PubMed ID: 21482572
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients.
Rolston KVI; Jamal MA; Nesher L; Shelburne SA; Raad I; Prince RA
Int J Antimicrob Agents; 2017 Apr; 49(4):416-421. PubMed ID: 28257904
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
31. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Sader HS; Flamm RK; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
[TBL] [Abstract][Full Text] [Related]
32. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
33. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species.
Jones RN; Flamm RK; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):89-93. PubMed ID: 23023107
[TBL] [Abstract][Full Text] [Related]
34. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
35. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
Clark C; McGhee P; Appelbaum PC; Kosowska-Shick K
Antimicrob Agents Chemother; 2011 May; 55(5):2344-51. PubMed ID: 21343467
[TBL] [Abstract][Full Text] [Related]
36. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
37. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Garrison MW; Kawamura NM; Wen MM
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
[TBL] [Abstract][Full Text] [Related]
38. Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011).
Sader HS; Jones RN; Stilwell MG; Flamm RK
Int J Antimicrob Agents; 2014 Mar; 43(3):284-6. PubMed ID: 24342717
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
40. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
Steed ME; Rybak MJ
Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
